What is the share price of Piramal Pharma Ltd (PPLPHARMA) today?
The share price of PPLPHARMA as on 23rd June 2025 is ₹194.29. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Piramal Pharma Ltd (PPLPHARMA) share?
The past returns of Piramal Pharma Ltd (PPLPHARMA) share are- Past 1 week: -3.10%
- Past 1 month: -3.50%
- Past 3 months: -14.35%
- Past 6 months: -23.93%
- Past 1 year: 23.76%
- Past 3 years: N/A%
- Past 5 years: 4.71%
What are the peers or stocks similar to Piramal Pharma Ltd (PPLPHARMA)?
The peers or stocks similar to Piramal Pharma Ltd (PPLPHARMA) include:What is the dividend yield % of Piramal Pharma Ltd (PPLPHARMA) share?
The current dividend yield of Piramal Pharma Ltd (PPLPHARMA) is 0.07.What is the market cap of Piramal Pharma Ltd (PPLPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Piramal Pharma Ltd (PPLPHARMA) is ₹25737.48 Cr as of 23rd June 2025.What is the 52 week high and low of Piramal Pharma Ltd (PPLPHARMA) share?
The 52-week high of Piramal Pharma Ltd (PPLPHARMA) is ₹307.90 and the 52-week low is ₹145.25.What is the PE and PB ratio of Piramal Pharma Ltd (PPLPHARMA) stock?
The P/E (price-to-earnings) ratio of Piramal Pharma Ltd (PPLPHARMA) is 282.43. The P/B (price-to-book) ratio is 3.25.Which sector does Piramal Pharma Ltd (PPLPHARMA) belong to?
Piramal Pharma Ltd (PPLPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Piramal Pharma Ltd (PPLPHARMA) shares?
You can directly buy Piramal Pharma Ltd (PPLPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Piramal Pharma Ltd
PPLPHARMA Share Price
194.290.42% (-0.81)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PPLPHARMA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PPLPHARMA Performance & Key Metrics
PPLPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 283.60 | 3.27 | 0.07% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.51 | 6.52 | 0.85% |
100%
Analysts have suggested that investors can buy this stock
from 10 analysts
Price Upside
Earnings Growth
Rev. Growth
PPLPHARMA Company Profile
Piramal Pharma Limited provides a diverse range of pharmaceutical products globally, including contract development and manufacturing services across various therapeutic areas.
SUNPHARMA
PE Ratio
36.56
36.56
1Y Return
11.24%
11.24%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
22.97
22.97
1Y Return
0.35%
0.35%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.50
19.50
1Y Return
8.83%
8.83%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
56.09
56.09
1Y Return
11.44%
11.44%
Buy Reco %
72.00
72.00
ZYDUSLIFE
PE Ratio
21.28
21.28
1Y Return
12.08%
12.08%
Buy Reco %
46.43
46.43
PPLPHARMA Forecast
PPLPHARMA Forecasts
Price
Revenue
Earnings
PPLPHARMA Share Price Forecast
PPLPHARMA Share Price Forecast
2025
Current
₹194.29
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹194.29
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
PPLPHARMA Company Revenue Forecast
PPLPHARMA Company Revenue Forecast
2025
Current
₹9.36
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹9.36
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
PPLPHARMA Stock EPS (Earnings Per Share) Forecast
PPLPHARMA Stock EPS (Earnings Per Share) Forecast
2025
Current
₹0.69
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹0.69
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
PPLPHARMA
PPLPHARMA
Income
Balance Sheet
Cash Flow
Annual Normal View
PPLPHARMA Income Statement
PPLPHARMA Income Statement
Annual Normal View
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,544.48 | 6,893.93 | 7,360.99 | 8,406.04 | 9,358.92 | 9,358.92 | ||||||
Raw Materials | 2,111.85 | 2,396.03 | 2,634.66 | 3,152.60 | 7,706.35 | 7,706.35 | ||||||
| Power & Fuel Cost | 136.70 | 163.56 | 207.81 | 241.59 | ||||||||
| Employee Cost | 1,467.74 | 1,588.83 | 1,896.35 | 2,029.50 | ||||||||
| Selling & Administrative Expenses | 709.63 | 868.15 | 917.47 | 994.33 | ||||||||
| Operating & Other expenses | 461.02 | 607.95 | 803.98 | 619.67 | ||||||||
EBITDA | 1,657.54 | 1,269.41 | 900.72 | 1,368.35 | 1,652.57 | 1,652.57 | ||||||
| Depreciation/Amortization | 545.04 | 586.18 | 676.69 | 740.57 | 816.34 | 816.34 | ||||||
| PBIT | 1,112.50 | 683.23 | 224.03 | 627.78 | 836.23 | 836.23 | ||||||
| Interest & Other Items | 163.45 | 198.25 | 344.18 | 448.49 | 421.59 | 421.59 | ||||||
| PBT | 949.05 | 484.98 | -120.15 | 179.29 | 414.64 | 414.64 | ||||||
| Taxes & Other Items | 114.02 | 109.02 | 66.31 | 161.47 | 323.51 | 323.51 | ||||||
| Net Income | 835.03 | 375.96 | -186.46 | 17.82 | 91.13 | 91.13 | ||||||
| EPS | 8.20 | 3.37 | -1.53 | 0.14 | 0.69 | 0.69 | ||||||
| DPS | 0.00 | 0.55 | 0.00 | 0.11 | 0.14 | 0.11 | ||||||
| Payout ratio | 0.00 | 0.16 | 0.00 | 0.79 | 0.20 | 0.16 |
PPLPHARMA Company Updates
FY 2025FY 2025
Investor Presentation
May 14PDF
Jan 28PDF
Oct 23PDF
Sep 24PDF
PPLPHARMA Stock Peers
PPLPHARMA Past Performance & Peer Comparison
PPLPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Piramal Pharma Ltd | 283.60 | 3.27 | 0.07% |
| Sun Pharmaceutical Industries Ltd | 36.56 | 5.95 | 0.96% |
| Cipla Ltd | 22.97 | 4.52 | 1.07% |
| Dr Reddy's Laboratories Ltd | 19.50 | 3.90 | 0.61% |
PPLPHARMA Stock Price Comparison
Compare PPLPHARMA with any stock or ETFCompare PPLPHARMA with any stock or ETF
PPLPHARMA
PPLPHARMA Holdings
PPLPHARMA Shareholdings
PPLPHARMA Promoter Holdings Trend
PPLPHARMA Promoter Holdings Trend
PPLPHARMA Institutional Holdings Trend
PPLPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PPLPHARMA Shareholding Pattern
PPLPHARMA Shareholding Pattern
PPLPHARMA Shareholding History
PPLPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in PPLPHARMA
Mutual Funds Invested in PPLPHARMA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Piramal Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 6.8122% | Percentage of the fund’s portfolio invested in the stock 2.30% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 36/67 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.8324% | Percentage of the fund’s portfolio invested in the stock 2.53% | Change in the portfolio weight of the stock over the last 3 months -0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 13/35 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5406% | Percentage of the fund’s portfolio invested in the stock 1.12% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 70/106 (-3) |
Compare 3-month MF holding change on Screener
smallcases containing PPLPHARMA stock
smallcases containing PPLPHARMA stock
Looks like this stock is not in any smallcase yet.
PPLPHARMA Events
PPLPHARMA Events
PPLPHARMA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PPLPHARMA Dividend Trend
No dividend trend available
PPLPHARMA Upcoming Dividends
PPLPHARMA Upcoming Dividends
Cash Dividend
Ex DateEx DateJul 16, 2025
Final
Final | Div/Share: ₹0.14
Dividend/Share
₹0.14
Ex DateEx Date
Jul 16, 2025
PPLPHARMA Past Dividends
PPLPHARMA Past Dividends
Cash Dividend
Ex DateEx DateJul 12, 2024
Final
Final | Div/Share: ₹0.11
Dividend/Share
₹0.11
Ex DateEx Date
Jul 12, 2024
PPLPHARMA Stock News & Opinions
PPLPHARMA Stock News & Opinions
Articles & Videos
Corporate
Piramal Pharma to conduct AGM
Piramal Pharma announced that the 5th Annual General Meeting(AGM) of the company will be held on 30 July 2025.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Piramal Pharma's Aurora unit completes USFDA inspection
Piramal Pharma announced that the US FDA conducted a general GMP (Good Manufacturing Practices) Inspection of Piramal Pharma's facility at Aurora, Canada from 26 May 2025 to 30 May 2025. The inspection was completed successfully with Zero Form - 483 observations and No Action Indicated (NAI) designation.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Spotlight
Piramal Pharma's Canada facility gets zero USFDA observation
According to a regulatory filing, the inspection was carried out from 26 May 2025 to 30 May 2025. At the conclusion of the inspection, the USFDA issued a zero-observation report in Form 483 and granted a no action indicated (NAI) designation. The company remains dedicated to maintaining the highest standards of compliance. Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The company's consolidated net profit jumped 51.6% to Rs 153.50 crore on 7.9% rise in revenue from operations to Rs 2,754.07 crore in Q4 FY25 over Q4 FY24. Shares of Piramal Pharma rose 0.36% to Rs 207.05 on the BSE. Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Piramal Pharma allots 35 lakh equity shares under ESOP
Piramal Pharma has allotted 35 lakh equity shares under ESOP on 21 May 2025. Consequent to this allotment, the paid-up share capital of the Company stands increased from to Rs. 1329,24,81,300 (consisting of 132,92,48,130 equity shares of face value of Rs. 10/- each). Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Piramal Pharma recommends final dividend
Piramal Pharma announced that the Board of Directors of the Company at its meeting held on 14 May 2025, inter alia, have recommended the final dividend of Rs 0.14 per equity Share (i.e. 1.4%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Piramal Pharma consolidated net profit rises 51.58% in the March 2025 quarter
Net profit of Piramal Pharma rose 51.58% to Rs 153.50 crore in the quarter ended March 2025 as against Rs 101.27 crore during the previous quarter ended March 2024. Sales rose 7.90% to Rs 2754.07 crore in the quarter ended March 2025 as against Rs 2552.36 crore during the previous quarter ended March 2024. For the full year,net profit rose 411.39% to Rs 91.13 crore in the year ended March 2025 as against Rs 17.82 crore during the previous year ended March 2024. Sales rose 11.99% to Rs 9151.18 crore in the year ended March 2025 as against Rs 8171.16 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2754.072552.36 8 9151.188171.16 12 OPM %20.3720.76 -15.7914.64 - PBDT515.56454.13 14 1230.98982.65 25 PBT272.80258.00 6 414.64242.08 71 NP153.50101.27 52 91.1317.82 411 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Piramal Pharma standalone net profit rises 1.53% in the March 2025 quarter
Net profit of Piramal Pharma rose 1.53% to Rs 277.27 crore in the quarter ended March 2025 as against Rs 273.08 crore during the previous quarter ended March 2024. Sales rose 10.78% to Rs 1689.80 crore in the quarter ended March 2025 as against Rs 1525.30 crore during the previous quarter ended March 2024. For the full year,net profit rose 76.73% to Rs 691.40 crore in the year ended March 2025 as against Rs 391.22 crore during the previous year ended March 2024. Sales rose 20.40% to Rs 5285.71 crore in the year ended March 2025 as against Rs 4390.11 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1689.801525.30 11 5285.714390.11 20 OPM %24.6525.55 -19.6814.08 - PBDT425.53415.17 2 1133.23712.88 59 PBT364.36362.67 0 911.14507.62 79 NP277.27273.08 2 691.40391.22 77 Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA
According to the company's exchange filing, the US FDA conducted a general Good Manufacturing Practices (GMP) inspection at the Turbhe facility from 11 February to 17 February 2025. Following the inspection, the US FDA has issued an EIR with a classification of voluntary action indicated (VAI). The receipt of the EIR signifies the successful closure of the inspection. Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The pharmaceutical company's consolidated net profit tumbled 63.6% to Rs 3.68 crore despite a 12.54% increase in revenue from operations to Rs 2,204.22 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Piramal Pharma's Turbhe facility successfully completes USFDA inspection
Piramal Pharma announced that the USFDA has issued an Establishment Inspection Report (EIR) for the company's Turbhe facility with Voluntary Action Indicated. The General Good Manufacturing Practices inspection inspection of the said facility was conducted between 11 February to 17 February 2025. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Piramal Pharma to conduct board meeting
Piramal Pharma will hold a meeting of the Board of Directors of the Company on 14 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant